Description
Spirocyclopropylene bridged nucleic
acid (scpBNATM) is a tricyclic analog of locked nucleic acid (LNA).
scpBNA exhibits high binding affinity as well as excellent metabolic
stability, and these properties make scpBNA an excellent sugar
modification for therapeutic applications.
Details
Usage
- Coupling: 3 minute coupling time recommended. Increase oxidation time 3 fold for optimal performance.
- Deprotection: No changes needed from standard method recommended by synthesizer manufacturer
| Specifications |
| Diluent |
Anhydrous Acetonitrile |
| Storage |
Freezer storage, -10 to -30°C, dry |
| Stability |
1-2 Days |
Intellectual Property
scpBNA™ is a trademark owned by Luxna Biotech Co., Ltd. (Luxna).
scpBNA™ phosphoramidites (Products) are protected by WO2015/125783A1,
WO2020/204022A1 and their foreign patents/applications controlled by
Luxna.
Glen Research sells the Products under contract with Summit
Pharmaceuticals International Corporation, which has the license from
Luxna. The resale of the Products is prohibited. The Products can be
used only for experimental or research use, and the uses of the
Products, including processed products thereof, for any purposes other
than experimental or research use is prohibited. The purchase of the
Products does not grant any right for the Patents, except for
experimental or research use. For any other use, the customer must
obtain a license from Luxna (sales@luxnabiotech.co.jp, 81-6-6170-1228).
Dilution/Coupling Data
The table below show pack size data and, for solutions, dilution and approximate coupling based on normal priming procedures.
ABI 392/394
Safety Data Sheet (EU)
Safety Data Sheet (Other)
Glen Report 36-21: Spirocyclopropylene bridged nucleic acid (scpBNA™) Phosphoramidites
Glen Report 36-22: New Products Spirocyclopropylene Bridged Nucleic Acids
If you cannot find the answer to your problem then please contact us or telephone +44 (0)1954 210 200